Thymosin Alpha-1
Tα1 / Zadaxin (Immune Modulator)
Also known as: Thymalfasin, Zadaxin
Last updated May 13, 2026
What is Thymosin Alpha-1?
Thymosin Alpha-1 carries the most extensive international approval and human-safety data record of any compound on the FDA’s Category 2 list. Approved as a pharmaceutical in over 35 countries, with 11,000+ human subjects studied, it remains restricted for compounding in the United States.
Thymosin Alpha-1 is a 28-amino-acid peptide originally isolated from the thymus gland — the small organ behind your sternum responsible for producing and training your immune system’s T-cells. Your thymus is most active in childhood and begins shrinking starting in your twenties. By age 50, it has significantly atrophied, which is a major contributor to age-related immune decline (immunosenescence).
Tα1 is an immunomodulator, not an “immune booster.” Rather than broadly increasing immune activity (which could worsen autoimmune conditions), it appears to support balanced immune function, enhancing responses that are too weak while potentially calming responses that are overactive. The proposed mechanism involves activity at Toll-like receptors on dendritic cells, supporting T-cell maturation and modulating the interplay between different arms of the immune system.
PCAC reviewed Tα1 in December 2024 and voted against inclusion on the 503A bulks list.
What Does the Research Actually Show?
Multiple RCTs showing Tα1 alone or with interferon significantly improves sustained virologic response. Basis for approval in 35+ countries. Phase III trials for hepatitis C conducted in the U.S.
Clinical studies show significantly improved influenza vaccine response in elderly and immunocompromised patients who typically mount poor responses.
Extensive evidence supporting enhanced CD4+ and CD8+ T-cell function, dendritic cell maturation and restored immune competence. A 2024 review of 30+ trials concluded Tα1 is “a well-tolerated and effective immune modulator.”
Improved overall survival in non-small-cell lung cancer and liver cancer as an adjunct. Reduced chemotherapy-induced lymphopenia. Not a cancer treatment — an immune modulator used alongside standard oncology.
Tα1 has been studied across acute severe infections including sepsis and COVID-19 with mixed clinical results. It has been used clinically in China for sepsis, but the 2025 TESTS trial (BMJ) found no evidence of reduced 28-day mortality. In severe COVID-19, retrospective studies showed reduced cytokine storms and reversed T-cell exhaustion. These results are promising but not definitive — no large prospective RCTs have confirmed benefit in either indication.
It’s worth noting: without controlled human trials, we can’t rule out that practitioner-reported benefits are placebo, coincidental with other interventions or overstated. The mechanistic rationale is sound, but sound rationale isn’t proof.
How Is Thymosin Alpha-1 Administered?
| Route | Subcutaneous injection |
| Dosage range | 1.6 mg per dose (Zadaxin clinical reference) |
| Frequency | 2–3x weekly (maintenance); daily for 1–2 weeks (acute immune support loading) |
| Protocol | Loading and maintenance phases vary by indication; clinical practice varies between providers |
| Access | PCAC-rejected for 503A inclusion December 2024; narrow patient-specific compounding exceptions only |
For phase-by-phase response timing and biomarker tracking, see our What to Expect on Thymosin Alpha-1 →
What Are the Side Effects and Risks?
- Injection site irritation — mild and the most commonly reported side effect.
- Compounding quality risk — the FDA flagged that compounded Tα1 may pose immunogenicity risk depending on manufacturing quality. This is a compounding concern, not a molecule concern. Verify pharmacy sourcing.
- Theoretical autoimmune concern — as an immune modulator, discuss with your provider if you have an autoimmune history. Clinical data has not shown worsening.
Who Should NOT Use Thymosin Alpha-1?
If you have an active autoimmune condition: Tα1 is modulatory rather than purely stimulatory, and clinical data has not shown worsening of autoimmune conditions. But the theoretical concern is real, and the conversation belongs with the specialist managing your autoimmune disease, not just your peptide provider.
If you are receiving cancer treatment: Tα1 has been studied in oncology adjuvant settings and may have a role alongside standard treatment in specific cancers. But it is not a cancer therapy, and combining it with chemotherapy, radiation or immune checkpoint inhibitors should be coordinated with your oncologist — not added independently.
If you are pregnant or breastfeeding: Despite extensive trial data in other populations, Tα1 has not been adequately studied in pregnancy or lactation. Absolute contraindication.
If your provider can’t verify their compounding pharmacy: The FDA flagged immunogenicity risk specifically tied to compounding quality. If your provider can’t name their pharmacy, confirm USP compliance or explain their third-party testing, that is a hard stop — not because of Tα1 itself, but because immunogenic impurities in an immunomodulatory drug are exactly the wrong thing to introduce.
The lag in CRP response is worth understanding before drawing conclusions from a single result.
Before You Start: Get Baseline Labs
We recommend baseline lab work before starting any peptide protocol so you and your provider can track changes. Key markers include CBC with differential, immune panel (CD4/CD8 ratio, NK cell activity if available), CMP and inflammatory markers.
Ask your provider about ordering these labs, or search for direct-to-consumer lab testing services in your area.
Order at-home labs from Everlywell →Lab recommendations are the same regardless of which service you use.
What You'll Need
If your provider prescribes an injectable protocol, you'll need basic supplies.
- Bacteriostatic Water (30ml)Link coming soon
- Insulin Syringes 29 gauge (100ct)Link coming soon
- Alcohol Prep Pads (200ct)Link coming soon
- Sharps ContainerLink coming soon
Supply links are affiliate links. We may earn a commission at no cost to you. We only link to commodity supplies, never to peptide products.
- 1Based on my immune labs (CD4/CD8 counts, NK cell activity), am I a good candidate?
- 2Are you prescribing this for general immune optimization or a specific condition? What outcome are we measuring?
- 3Which compounding pharmacy are you sourcing from? Do they hold current USP compliance?
- 4What monitoring schedule and immune markers will we track?
- 5I have [autoimmune condition/cancer history] — is Tα1 appropriate?
- 6What's the prescription pathway for compounded Tα1 vs internationally-sourced Zadaxin? What access constraints should I know about?
Is Thymosin Alpha-1 Legal in 2026?
Not broadly FDA-approved in the United States, though Tα1 holds FDA orphan drug designations for several conditions. Category 2 since late 2023. Referred to PCAC in September 2024 alongside CJC-1295, Ipamorelin, AOD-9604 and Selank. The committee reviewed Tα1 and voted against inclusion on the 503A bulks list in December 2024.
This is an unusual regulatory outcome. Thymosin Alpha-1 has the strongest international evidence base of any peptide on the Category 2 list — approved as Zadaxin in 35+ countries, more than 11,000 subjects of safety data, decades of clinical use. But the outcome is the outcome: there is no current FDA path to legal compounding for Tα1 in the United States outside narrow patient-specific 503A exceptions, where a prescriber documents specific clinical need that the FDA-approved alternatives do not address.
How Do I Get Thymosin Alpha-1 Through a Legitimate Provider?
No verified providers currently meet our evaluation criteria for this compound. Subscribe to be notified when that changes.
When provider links go live, we’ll disclose all affiliate relationships here.